SCTX 8-K 2026-09-02

Scribe Therapeutics, Inc. (SCTX) 8-K dated 2026-09-02 — accession 0001193125-26-380184.

Scribe Therapeutics, Inc. (SCTX) common stock.

Scribe Therapeutics, Inc. filed a 8-K on 2026-09-02. Accession 0001193125-26-380184.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported SCTX revenue for 2026-06-30 was $1.9M. Net income was -$6.5M. Revenue was down 60.8% from 2025-06-30 to 2026-06-30.

Not investment advice. The SCTX SEC hub lists recent forms. The stock page is the research view.